Hematology Home >
- Faculty
Lynn Mara Schuchter, M.D.Professor of Medicine at the Hospital of the University of Pennsylvania
Associate Director, Clinical Research Unit
Program Leader: Melanoma Program
Division Chief, Hematology-Oncology
Department: Medicine
Contact information
Hospital of the University of Pennsylvania
3400 SPRUCE ST., 1218 Penn Tower 4283 Philadelphia, PA 19104
Office: 215-662-4859
Fax: 215-349-5866
Education:
BS University of Michigan, 1978. M.D. Chicago Medical School, 1982.
Post-Graduate Training
Intern, Department of Medicine , Michael Reese Hospital, Chicago, IL, 1982-1983. Resident, Department of Medicine, Michael Reese Hospital, Chicago, IL, 1983-1985. Chief Medical Resident, Department of Medicine, Michael Reese Hospital, Chicago, IL, 1985-1986. Clinical Fellow, Medical Oncology, The Johns Hopkins Oncology Center Baltimore, MD, 1986-1989. Visiting Fellow, Biologic Response Modifier Program, NCI, Frederick, MD, 1987-1987.
Certifications
Permanent linkAmerican Board of Internal Medicine (Internal Medicine) , 1986. American Board of Internal Medicine Subspecialty Certification in Medical Oncology, 1990. Selected PublicationsL. Kruper and L. Schuchter: Malignant Melanoma and Non-Melanoma Skin Cancer in the Elderly. Second Edition. Multidisciplinary Treatment and Management of Cancer in the Elderly. Muss HB, Johnson KA, Hunter CP (eds.). Marcel Dekker, In Press.Kruper L,Botbyl J, Czerniecki B, Elder D, Fraker D, Ming M, Schuchter L, Spitz F, Guerry D, Gimotty: Predicting sentinel lymph node status in stage I/II melanoma. Proc ASCO 23(16s): 7501, June 2005. Domchek, SM, Fox KR, Recio A, Schuchter LM, Davidson R, Demichele, A, Feldman M, Vonderheide RH.: Telomerase vaccination of metastatic breast cancer patients induces antigen-specific tumor infiltrating lymphocytes and tumor necrosis. Proc ASCO 23(16S), June 2005. Flaherty, KT, Redlinger M, Schuchter LM, Lathia CD, Weber BL, O'Dwyer PJ.: Phase I/II pharmacokinetic and pharmacokinetic trial of BAY 43-9006 alone in patients with metastatic melanoma. ProcASCO 23(16S), June 2005. Schuchter, LM: 2010: A Target Date for Improving Survival of Patients with Metastatic Melanoma. ASCO Educational Book. Michael C. Perry, MD (eds.). Lisa Greaves, Spring: 648-649, 2005. Smith, K, Wray L, Klein-Cabral, M, Schuchter L, Fox K, Glick J, DeMichele A.: Ethnic Disparities in Adjuvant Chemotherapy for Breast Cancer are not Caused by Excess Toxicity in Black Patients. Clinical Breast 6(3): 260-266, August 2005. Gimotty, P.A., Guerry, D., Ming, M., Elenitsas, R., Xu, G., Czerniecki, B., Spitz, F., Schuchter, L., Elder, D.: Thin Primary Cutaneous Malignant Melanoma: A Prognostic Tree for Ten-Year Metastasis is More Accurate than AJCC Staging. Journal of Clinical Oncology 22(18): 3668-76, Sept 2004. Fuster, D., Chiang, S., Johnson, G., Schuchter, L.M., Zhuang, H., Alavi, A.: Is 18F-FDG PET More Accurate Than Standard Diagnostic Procedures in the Detection of Suspected Recurrent Melanoma? Journal of Nuclear Medicine 45(8): 1323-1327, 2004. Alton, J., Jacobs, L., Fox, K., Schuchter, L., Domchek, S., Glick, J., Meadows, A., DeMichele, A.: Chemotherapy-related Amenorrhea (CRA) in Breast Cancer Survivors: Impact of Taxanes on Ovarian Function. San Antonio Breast Meetings 2004. Schuchter, L.M.: Adjuvant Interferon Therapy for Melanoma: High-dose, Low-dose, No dose, Which dose? J Clin Oncol 1: 7-10, 2004.
|
